Skip to search formSkip to main contentSkip to account menu

Panzem

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
PurposeAngiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2… 
Highly Cited
2011
Highly Cited
2011
SummaryPurpose: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity… 
Review
2009
Review
2009
C2- and C4-position 17beta-estradiol metabolites play an important role in breast carcinogenesis. 2-Hydroxyestradiol and 4… 
Highly Cited
2009
Highly Cited
2009
Purpose: 2-Methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17β metabolite that at pharmacologic doses exerts… 
2009
2009
e16116 Background: Panzem NCD (2ME2) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic… 
Highly Cited
2008
Highly Cited
2008
Clinical studies using the microtubule-targeting agent 2-methoxyestradiol (2ME2; Panzem) in cancer patients show that treatment… 
2007
2007
A14 Background: 2-methoxyestradiol (2ME2; Panzem ® ) inhibits tumor cell proliferation and induces apoptosis by inhibiting… 
2005
2005
3415 2-Methoxyestradiol (2ME2, Panzem®) is an endogenous metabolite of estradiol that effectively inhibits a wide range of cancer…